海南双成药业股份有限公司 独立董事 2024 年度述职报告 （肖建华） 我作为海南双成药业股份有限公司（以下简称"公司"）的独立董事，2024 年度我严格按照《公司法》《上市公司独立董事规则》《公司章程》公司《独立董 事制度》等相关法规制度的规定和要求，忠实履行独立董事的职责，充分发挥独 立董事的作用。现将在 2024 年履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 肖建华先生，男，1972 年出生，大专学历，高级会计师，注册会计师，曾 任职于海南从信会计师事务所、中准会计师事务所海南分所、海南永信德威会计 师事务所、中兴财光华会计师事务所（特殊普通合伙）海南分所、中同（海南） 会计师事务所（普通合伙）、海南晨海水产有限公司、海南中瑞恒信税务师事务 所有限责任公司、海南荣鑫胜会计师事务所等单位，曾任闻泰科技股份有限公司 独立董事。现任海南国瑞华健会计师事务所（普通合伙）副所长，兼任和润达企 业管理咨询（海南）有限公司董事和总经理，公司独立董事。 （二）独立性说明 公司现有2名独立董事，独立董事人数及任职资格符合相关法律法规中关于 上市公司独立董事人数比例和 ...

海南双成药业股份有限公司 独立董事 2024 年度述职报告 （李建伟） 我作为海南双成药业股份有限公司（以下简称"公司"）的独立董事，2024 年度我严格按照《公司法》《上市公司独立董事规则》《公司章程》、公司《独立 董事制度》等相关法规制度的规定和要求，忠实履行独立董事的职责，充分发挥 独立董事的作用。现将在 2024 年履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 李建伟先生，中国国籍，无境外居留权，1986 年出生，硕士研究生学历， 毕业于海南大学法学专业。2015 年 8 月至 2021 年 4 月曾任河南文丰律师事务所 律师、2021 年 5 月至 2022 年 3 月曾任北京京师（三亚）律师事务所律师、2022 年 4 月至 2023 年 2 月曾任海南领迈律师事务所律师、2023 年 3 月至 2023 年 10 月曾任北京德恒律师事务所律师；2023 年 11 月至今担任北京市百瑞律师事务所 高级合伙人、律师，现任公司独立董事。 （二）独立性说明 公司现有2名独立董事，独立董事人数及任职资格符合相关法律法规中关于 上市公司独立董事人数比例和 ...

海南双成药业股份有限公司董事会 2025 年 4 月 27 日 经核查独立董事肖建华先生、李建伟先生的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》中对独立董事独立性的相关要求。 海南双成药业股份有限公司董事会 关于独立董事独立性自查情况的专项意见 根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等要求，海南双成药业股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事肖建华先生、李建伟先生的独立 性情况进行评估并出具如下专项意见： ...

海南双成药业股份有限公司 股东会网络投票实施细则 海南双成药业股份有限公司 股东会网络投票实施细则 （2025 年 4 月修订） 第一章 总则 第一条 为规范海南双成药业股份有限公司(以下简称"公司")股东会网络 投票业务，保护投资者合法权益，根据《规范运作指引》《深圳证券交易所股票上 市规则》、《深圳证券交易所上市公司股东会网络投票实施细则》、《公司章程》及 其他有关规定，制订本细则。 第二条 本细则适用于公司利用深圳证券交易所股东会网络投票系统向其股 东提供股东会网络投票服务。 第三条 本细则所称股东会网络投票系统(以下简称"网络投票系统")是指 深圳证券交易所利用网络与通信技术，为公司股东行使股东会表决权提供服务的 信息技术系统。 网络投票系统包括深圳证券交易所交易系统、互联网投票系统(网址： http://wltp.cninfo.com.cn)。 公司可以选择使用现场投票辅助系统收集汇总现场投票数据，并委托深圳证 券信息有限公司(以下简称"信息公司")合并统计网络投票和现场投票数据。 第四条 公司召开股东会,除现场会议投票外，应当向股东提供股东会网络投 票服务。 第七条 公司在股东会通知中,应当对网络 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥36,675,823.05, a decrease of 14.23% compared to ¥42,761,740.63 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥10,040,496.02, representing a decline of 14.84% from a loss of ¥8,742,676.77 in the previous year[4] - The company's basic and diluted earnings per share were both -¥0.0242, a decrease of 14.69% from -¥0.0211 in the same period last year[4] - Net loss attributable to the parent company was CNY -10,040,496.02, compared to CNY -8,742,676.77 in the previous period, indicating a worsening of approximately 14.8%[20] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥4,836,758.99, a 79.54% increase compared to a net outflow of ¥23,640,127.59 last year[4] - The net cash flow from operating activities was -$4,836,758.99, an improvement from -$23,640,127.59 in the previous period[22] - Cash inflow from operating activities was CNY 41,202,488.27, down from CNY 46,288,023.21, a decrease of about 10.4% year-over-year[21] - Total cash outflow from operating activities decreased to $46,039,247.26 from $69,928,150.80[22] - Cash inflow from investment activities increased significantly to $86,578,478.38 compared to $46,581,555.73 in the prior period[22] - The net cash flow from investment activities was -$36,775,305.73, a decline from $13,456,988.93 previously[22] - Cash inflow from financing activities totaled $3,709,560.00, down from $25,931,612.24 in the last period[22] - The net cash flow from financing activities was -$147,635.85, a significant drop from $24,469,778.91[22] - The net increase in cash and cash equivalents decreased by 391.43% compared to the previous year, influenced by operating, investing, and financing activities[10] - The ending balance of cash and cash equivalents decreased to $3,439,716.44 from $17,684,279.51[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥762,219,967.93, down 2.76% from ¥783,866,026.52 at the end of the previous year[4] - Total current assets decreased from 155,969,514.43 RMB to 136,752,293.30 RMB, a reduction of approximately 12.3%[16] - Total liabilities decreased to CNY 364,114,607.47 from CNY 372,260,377.26, a decline of approximately 2.9%[17] - Current liabilities totaled CNY 170,971,610.83, down from CNY 176,987,637.83, reflecting a decrease of about 3.4%[17] - Non-current liabilities decreased to CNY 193,142,996.64 from CNY 195,272,739.43, a reduction of approximately 1.1%[17] - Total equity decreased to CNY 398,105,360.46 from CNY 411,605,649.26, indicating a decline of about 3.3%[17] Expenses - Sales expenses decreased by 47.94% year-on-year, primarily due to reduced product sales and lower market development investments[9] - R&D expenses fell by 50.95% compared to the previous year, reflecting a decrease in research investments[9] - Total operating costs decreased to CNY 51,367,471.72 from CNY 57,356,433.81, a reduction of about 10.4% year-over-year[19] Other Income and Transactions - Other income increased by 197.15% year-on-year, mainly due to higher government subsidy income[9] - The total amount of related party transactions with Ningbo Shuangcheng Pharmaceutical Co., Ltd. is 3,748,680.00 RMB, covering a three-year contract[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 79,029[12] - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 32.92% of shares, totaling 136,516,546 shares[12] Strategic Decisions - The company plans to terminate the acquisition of 100% equity in Ningbo Aola Semiconductor Co., Ltd. due to disagreements on transaction terms[13] - The company is actively pursuing strategic transactions and partnerships to enhance its market position[13] Accounting and Audit - The company did not undergo an audit for the first quarter report[23] - The new accounting standards will be first implemented starting in 2025[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥174.21 million, a decrease of 26.16% compared to ¥235.93 million in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥78.30 million, representing a 54.32% increase in losses compared to a loss of ¥50.74 million in 2023[21]. - The net cash flow from operating activities for 2024 was negative ¥40.83 million, a decline of 450.76% compared to positive cash flow of ¥11.64 million in 2023[21]. - The total assets at the end of 2024 were approximately ¥783.87 million, a decrease of 2.41% from ¥803.25 million at the end of 2023[21]. - The net assets attributable to shareholders decreased by 16.56% to approximately ¥393.41 million at the end of 2024, down from ¥471.49 million at the end of 2023[21]. - The basic and diluted earnings per share for 2024 were both negative ¥0.19, a decline of 58.33% compared to negative ¥0.12 in 2023[21]. - The weighted average return on net assets for 2024 was negative 18.10%, a decrease of 7.86% from negative 10.24% in 2023[21]. - The company reported a significant increase in losses from non-recurring gains and losses, with a net profit of negative ¥71.71 million in 2024 compared to negative ¥24.14 million in 2023, marking a 197.05% increase in losses[21]. Revenue Breakdown - The company's total revenue for the first quarter was ¥42,761,740.63, while the fourth quarter revenue was ¥47,246,306.92, indicating fluctuations throughout the year[25]. - The net profit attributable to shareholders for the fourth quarter was -¥40,467,047.98, showing a significant loss compared to the first quarter's loss of -¥8,742,676.77[25]. - The net cash flow from operating activities was negative in three out of four quarters, with the highest cash flow of ¥3,797,914.60 occurring in the third quarter[25]. - The industrial segment generated CNY 129.21 million, representing 74.17% of total revenue, but saw a 40.89% decline compared to the previous year[53]. - The service sector revenue increased by 159.49% year-on-year, reaching CNY 45.00 million[53]. - The peptide product line accounted for 47.42% of total revenue, totaling CNY 82.61 million, down 27.00% from the previous year[53]. - The company reported a significant increase in contract research revenue, which rose by 223.05% to CNY 40.29 million[53]. Research and Development - Research and development investment for 2024 was CNY 39.97 million, accounting for 22.95% of operating revenue[46]. - The company is actively engaged in expanding its product pipeline and enhancing its research capabilities in response to evolving industry regulations and market demands[30]. - The company has advanced its research and development in polypeptide products, focusing on high market potential and complex synthesis[39]. - The company is currently developing multiple new products (SC-C139, SC-C116, SC-C140, SC-C143, SCH-009) aimed at enhancing its product line and core competitiveness[64]. - The company plans to accelerate R&D efforts, particularly in peptide APIs and formulations, while enhancing the sales team to boost product sales post-consistency evaluation[88]. Market and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue of ¥2,529.85 billion in 2024, with a profit total of ¥34.207 billion, reflecting a 1.1% decline from the previous year[29]. - The domestic pharmaceutical industry is experiencing a shift towards community hospitals and pharmacies, indicating a changing market landscape[84]. - The market for synthetic peptide drugs is expected to grow due to increasing demand driven by rising income levels and health awareness among residents[85]. - The company faces challenges from intensified competition in the peptide drug sector, including price reductions from centralized procurement policies[86]. Risk Factors - The company faces various risks including industry policy changes, drug price reductions, and financial risks, which may impact future operations[5]. - The company faces talent retention risks, particularly in high-level technical roles for new drug development, and is implementing diverse incentive mechanisms to attract and retain talent[97]. - Financial risks are highlighted due to increasing export business and potential foreign exchange fluctuations, with strategies in place to mitigate these risks through enhanced product value and financial management practices[97]. - The company is concerned about international trade environment risks that could affect resource availability and customer retention, potentially impacting production and costs[99]. Governance and Compliance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[104]. - The board of directors convened seven times, demonstrating diligence in governance and decision-making processes[106]. - The company has established a performance evaluation system for directors and senior management, ensuring transparency and accountability[106]. - The independent directors actively participated in decision-making and provided independent opinions on major issues[106]. - The company has established a robust financial accounting system, ensuring independent financial decision-making[111]. Environmental Initiatives - Environmental protection investments totaled approximately CNY 3.23 million, with upgrades to wastewater treatment systems and online monitoring systems implemented[48]. - The company achieved a 15% reduction in natural gas consumption after low-nitrogen transformation of two boilers, with nitrogen oxide emissions below 50 mg/Nm³[161]. - The company has implemented a dual A/O process for wastewater treatment to enhance pollutant treatment efficiency in 2024[160]. - The company has established an emergency response plan for environmental incidents, revised in May 2024, and conducted emergency drills[160]. Shareholder Commitments - The company has committed to fulfilling its obligations as a controlling shareholder and to ensure that related parties do not engage in transactions that infringe on the rights of other shareholders[166]. - The commitments are intended to prevent any conflicts of interest and ensure fair treatment of all shareholders[166]. - The company will ensure that any unavoidable related party transactions will comply with national laws and regulations, as well as the company's articles of association[168]. - The company will prioritize the acquisition of assets or equity related to competing businesses under equal conditions if such competition arises[168]. Dividend Policy - The company plans to distribute dividends in cash or a combination of cash and stock, prioritizing cash dividends[170]. - The company aims to maintain a cash dividend policy with a cumulative cash distribution of no less than 30% of the average distributable profit over the past three years[170]. - Cash dividends will be distributed annually, with conditions including positive distributable profits and sufficient cash flow[170].

邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...

抄底！中央汇金17.6亿重仓医药"双子星"，或将诞生下一个双成药业！ 注意！A股惊现"主力"百亿级抄底信号 资本市场正在见证历史性时刻！素有"金融稳定器"之称的中央汇金，继2019年精准抄底北方华创（股价 四年暴涨4800%）后，再度祭出重磅操作——斥资17.6亿元战略布局医药板块，其持仓动向或将催生年 度超级妖股！ 顶层设计定调万亿蓝图：4月2日，国家药监局发布《优化医疗器械全周期监管举措（征求意见稿）》， 剑指高端医疗器械创新生态构建，国务院办公厅此前明确规划：2029年医药产业规模突破2万亿，复合 增速超12%（远超GDP增速）。 硬核技术突破全球瞩目：海博为药业KRAS G12D抑制剂获FDA临床许可，全球首个攻克"不可成药"靶 点的中国药企，中国药企通过cGMP认证数量同比激增87%，国际化进程全面提速。 刚需市场持续扩容：联合国粮农组织最新预测：2040年全球兽用抗生素需求达12.9万吨，国内创新药市 场年均增速18.6%，慢病领域用药规模已突破6000亿。 国家队相中的"双子星"， 想知晓的朋友来 主 页 经过对十大券商研报的交叉验证，锁定两家获中央汇金重仓的医药核心标的： 信立泰，手握全球首个 ...

深股通专用席位一周上榜龙虎榜个股 | 代码 | 简称 | 深股通专用席位净买入（万元） | 一周涨跌幅（%） | 一周换手率（%） | | --- | --- | --- | --- | --- | | 002648 | 卫星化学 | 58960.09 | 21.43 | 25.48 | | 002261 | 拓维信息 | 23414.60 | 3.93 | 68.12 | | 300773 | 拉卡拉 | 8096.46 | 23.83 | 123.35 | | 300468 | 四方精创 | 6572.22 | -3.14 | 123.37 | | 002537 | 海联金汇 | 3224.96 | 46.57 | 80.36 | | 002085 | 万丰奥威 | 3150.73 | 14.72 | 23.36 | | 000601 | 韶能股份 | 2917.95 | 17.03 | 74.90 | | 002693 | 双成药业 | 1446.05 | -27.74 | 48.70 | | 301558 | 三态股份 | 1083.21 | -4.43 | 154.25 | | 301486 | 致 ...

| 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002693 | 双成药业 | -9.97 | 18.88 | -13065.36 | | 003020 | 立方制药 | -10.00 | 17.63 | -8292.64 | | 002422 | 科伦药业 | -6.60 | 2.41 | -7319.24 | | 600216 | 浙江医药 | -1.30 | 3.42 | -6123.73 | | 300233 | 金城医药 | -3.32 | 13.51 | -5509.62 | | 600789 | 鲁抗医药 | -1.52 | 12.60 | -4951.56 | | 600161 | 天坛生物 | -3.23 | 2.17 | -4569.02 | | 002643 | 万润股份 | -1.76 | 1.64 | -2570.25 | | 600721 | 百花医药 | -2.57 | 8.54 | -2336.75 | | 603882 | 金域医学 | -2.40 | 2.70 ...